Publication

Testing the McSad depression specific classification system in patients with somatic conditions: validity and performance

Papageorgiou, K., Vermeulen, K. M., Schroevers, M. J., Buskens, E. & Ranchor, A. V., 26-Jul-2013, In : HEALTH AND QUALITY OF LIFE OUTCOMES. 11, 10 p., 125.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Papageorgiou, K., Vermeulen, K. M., Schroevers, M. J., Buskens, E., & Ranchor, A. V. (2013). Testing the McSad depression specific classification system in patients with somatic conditions: validity and performance. HEALTH AND QUALITY OF LIFE OUTCOMES, 11, [125]. https://doi.org/10.1186/1477-7525-11-125

Author

Papageorgiou, Katerina ; Vermeulen, Karin M. ; Schroevers, Maya J. ; Buskens, Erik ; Ranchor, Adelita V. / Testing the McSad depression specific classification system in patients with somatic conditions : validity and performance. In: HEALTH AND QUALITY OF LIFE OUTCOMES. 2013 ; Vol. 11.

Harvard

Papageorgiou, K, Vermeulen, KM, Schroevers, MJ, Buskens, E & Ranchor, AV 2013, 'Testing the McSad depression specific classification system in patients with somatic conditions: validity and performance', HEALTH AND QUALITY OF LIFE OUTCOMES, vol. 11, 125. https://doi.org/10.1186/1477-7525-11-125

Standard

Testing the McSad depression specific classification system in patients with somatic conditions : validity and performance. / Papageorgiou, Katerina; Vermeulen, Karin M.; Schroevers, Maya J.; Buskens, Erik; Ranchor, Adelita V.

In: HEALTH AND QUALITY OF LIFE OUTCOMES, Vol. 11, 125, 26.07.2013.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Papageorgiou K, Vermeulen KM, Schroevers MJ, Buskens E, Ranchor AV. Testing the McSad depression specific classification system in patients with somatic conditions: validity and performance. HEALTH AND QUALITY OF LIFE OUTCOMES. 2013 Jul 26;11. 125. https://doi.org/10.1186/1477-7525-11-125


BibTeX

@article{205c0f05cdd9441588523a61c7a6cc06,
title = "Testing the McSad depression specific classification system in patients with somatic conditions: validity and performance",
abstract = "Background: Valuations of depression are useful to evaluate depression interventions offered to patients with chronic somatic conditions. The only classification system to describe depression developed specifically for valuation purposes is the McSad, but it has not been used among somatic patients. The aim of this study was to test the construct validity of the McSad among diabetes and cancer patients and then to compare the McSad to the commonly used EuroQol - 5 Dimensions (EQ-5D (TM)) classification system. The comparison was expected to shed light on their capacity to reflect the range of depression states experienced by somatic patients.Methods: Cross-sectional data were collected online from 114 diabetes and 195 cancer patients; additionally, 241 cancer patients completed part of the survey on paper. Correlational analyses were performed to test the construct validity. Specifically, we hypothesized high correlations of the McSad domains with depression (Center for Epidemiological Studies Depression Scale (CES-D) and the Patient Health Questionnaire (PHQ-9)). We also expected low/moderate correlations with self-esteem (Rosenberg Self-Esteem scale - RSE) and extraversion (Eysenck Personality Questionnaire Extraversion scale - EPQ-e). Multiple linear regression analyses were run so that the proportion of variance in depression scores (CES-D, PHQ-9) explained by the McSad could be compared to the proportion explained by the EQ-5D classification system.Results: As expected, among all patients groups, we found moderate to high correlations for the McSad domains with the CES-D (.41 to .70) and the PHQ-9 (.52 to .76); we also found low to moderate correlations with the RSE (-.21 to .-48) and the EPQ-e (.18 to .31). Linear regression analyses showed that the McSad explained a greater proportion of variance in depression (CES-D, PHQ-9) (Diabetes: 73{\%}, 82{\%}; Cancer: 72{\%}, 72{\%}) than the EQ-5D classification system (Diabetes: 47{\%}, 59{\%}; Cancer: 51{\%}, 47{\%}).Conclusions: Findings support the construct validity of the McSad among patients with somatic conditions and demonstrate that it performs better than the EQ-5D classification system to reflect the range of depression states. For future valuation purposes, the McSad classification system could therefore be recommended to describe depression as experienced by patients with a chronic medical condition.",
keywords = "EYSENCK PERSONALITY QUESTIONNAIRE, COGNITIVE-BEHAVIORAL THERAPY, RANDOMIZED CONTROLLED-TRIAL, QUALITY-OF-LIFE, SEROTONIN REUPTAKE INHIBITORS, COST-UTILITY ANALYSIS, SCALE CES-D, PRIMARY-CARE, MENTAL-HEALTH, CANCER-PATIENTS",
author = "Katerina Papageorgiou and Vermeulen, {Karin M.} and Schroevers, {Maya J.} and Erik Buskens and Ranchor, {Adelita V.}",
year = "2013",
month = "7",
day = "26",
doi = "10.1186/1477-7525-11-125",
language = "English",
volume = "11",
journal = "HEALTH AND QUALITY OF LIFE OUTCOMES",
issn = "1477-7525",
publisher = "BMC",

}

RIS

TY - JOUR

T1 - Testing the McSad depression specific classification system in patients with somatic conditions

T2 - validity and performance

AU - Papageorgiou, Katerina

AU - Vermeulen, Karin M.

AU - Schroevers, Maya J.

AU - Buskens, Erik

AU - Ranchor, Adelita V.

PY - 2013/7/26

Y1 - 2013/7/26

N2 - Background: Valuations of depression are useful to evaluate depression interventions offered to patients with chronic somatic conditions. The only classification system to describe depression developed specifically for valuation purposes is the McSad, but it has not been used among somatic patients. The aim of this study was to test the construct validity of the McSad among diabetes and cancer patients and then to compare the McSad to the commonly used EuroQol - 5 Dimensions (EQ-5D (TM)) classification system. The comparison was expected to shed light on their capacity to reflect the range of depression states experienced by somatic patients.Methods: Cross-sectional data were collected online from 114 diabetes and 195 cancer patients; additionally, 241 cancer patients completed part of the survey on paper. Correlational analyses were performed to test the construct validity. Specifically, we hypothesized high correlations of the McSad domains with depression (Center for Epidemiological Studies Depression Scale (CES-D) and the Patient Health Questionnaire (PHQ-9)). We also expected low/moderate correlations with self-esteem (Rosenberg Self-Esteem scale - RSE) and extraversion (Eysenck Personality Questionnaire Extraversion scale - EPQ-e). Multiple linear regression analyses were run so that the proportion of variance in depression scores (CES-D, PHQ-9) explained by the McSad could be compared to the proportion explained by the EQ-5D classification system.Results: As expected, among all patients groups, we found moderate to high correlations for the McSad domains with the CES-D (.41 to .70) and the PHQ-9 (.52 to .76); we also found low to moderate correlations with the RSE (-.21 to .-48) and the EPQ-e (.18 to .31). Linear regression analyses showed that the McSad explained a greater proportion of variance in depression (CES-D, PHQ-9) (Diabetes: 73%, 82%; Cancer: 72%, 72%) than the EQ-5D classification system (Diabetes: 47%, 59%; Cancer: 51%, 47%).Conclusions: Findings support the construct validity of the McSad among patients with somatic conditions and demonstrate that it performs better than the EQ-5D classification system to reflect the range of depression states. For future valuation purposes, the McSad classification system could therefore be recommended to describe depression as experienced by patients with a chronic medical condition.

AB - Background: Valuations of depression are useful to evaluate depression interventions offered to patients with chronic somatic conditions. The only classification system to describe depression developed specifically for valuation purposes is the McSad, but it has not been used among somatic patients. The aim of this study was to test the construct validity of the McSad among diabetes and cancer patients and then to compare the McSad to the commonly used EuroQol - 5 Dimensions (EQ-5D (TM)) classification system. The comparison was expected to shed light on their capacity to reflect the range of depression states experienced by somatic patients.Methods: Cross-sectional data were collected online from 114 diabetes and 195 cancer patients; additionally, 241 cancer patients completed part of the survey on paper. Correlational analyses were performed to test the construct validity. Specifically, we hypothesized high correlations of the McSad domains with depression (Center for Epidemiological Studies Depression Scale (CES-D) and the Patient Health Questionnaire (PHQ-9)). We also expected low/moderate correlations with self-esteem (Rosenberg Self-Esteem scale - RSE) and extraversion (Eysenck Personality Questionnaire Extraversion scale - EPQ-e). Multiple linear regression analyses were run so that the proportion of variance in depression scores (CES-D, PHQ-9) explained by the McSad could be compared to the proportion explained by the EQ-5D classification system.Results: As expected, among all patients groups, we found moderate to high correlations for the McSad domains with the CES-D (.41 to .70) and the PHQ-9 (.52 to .76); we also found low to moderate correlations with the RSE (-.21 to .-48) and the EPQ-e (.18 to .31). Linear regression analyses showed that the McSad explained a greater proportion of variance in depression (CES-D, PHQ-9) (Diabetes: 73%, 82%; Cancer: 72%, 72%) than the EQ-5D classification system (Diabetes: 47%, 59%; Cancer: 51%, 47%).Conclusions: Findings support the construct validity of the McSad among patients with somatic conditions and demonstrate that it performs better than the EQ-5D classification system to reflect the range of depression states. For future valuation purposes, the McSad classification system could therefore be recommended to describe depression as experienced by patients with a chronic medical condition.

KW - EYSENCK PERSONALITY QUESTIONNAIRE

KW - COGNITIVE-BEHAVIORAL THERAPY

KW - RANDOMIZED CONTROLLED-TRIAL

KW - QUALITY-OF-LIFE

KW - SEROTONIN REUPTAKE INHIBITORS

KW - COST-UTILITY ANALYSIS

KW - SCALE CES-D

KW - PRIMARY-CARE

KW - MENTAL-HEALTH

KW - CANCER-PATIENTS

U2 - 10.1186/1477-7525-11-125

DO - 10.1186/1477-7525-11-125

M3 - Article

VL - 11

JO - HEALTH AND QUALITY OF LIFE OUTCOMES

JF - HEALTH AND QUALITY OF LIFE OUTCOMES

SN - 1477-7525

M1 - 125

ER -

ID: 5929100